Zinbryta (multiple sclerosis) Zenapax (acute transplant rejection, discontinued in 2009)
AHFS/Drugs.com
zinbryta
Pregnancy category
AU: B3
Routes of administration
Subcutaneous injection, Intravenous
ATC code
L04AC01 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)[1]
CA: ℞-only[2]
US: ℞-only / Withdrawn[3]
In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability
90%
Metabolism
Proteases
Elimination half-life
21 days (11–38 days)
Identifiers
CAS Number
152923-56-3Y
DrugBank
DB00111Y
ChemSpider
none
UNII
CUJ2MVI71Y
KEGG
D03639N
ChEMBL
ChEMBL1201605N
Chemical and physical data
Formula
C6332H9808N1678O1989S42
Molar mass
142612.39 g·mol−1
NY (what is this?)(verify)
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[4][5][3]
^"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^ ab"FDA working with manufacturers to withdraw Zinbryta from the market in the United States". U.S. Food and Drug Administration (FDA). Retrieved 15 March 2018.
^"Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta". Reuters. 2018.
^Loftus P (2 March 2018). "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market". The Wall Street Journal.
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple...
spondylitis by their ability to bind to and inhibit TNF-α. Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help prevent acute rejection...
biological half-life of antibodies is typically on the order of days, see daclizumab and erenumab by way of example. To visualize and quantify the distribution...
(vemurafenib), for late-stage V600E BRAF mutation-positive melanoma. Zenapax (daclizumab), for the prevention of acute transplant rejection. Diabetes management...
Ocrelizumab Ozanimod Ponesimod Siponimod Teriflunomide Other treatments Former Daclizumab Research in multiple sclerosis Demyelinating diseases Other List of multiple...
the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty. Daclizumab became the first humanized monoclonal...
mouse/human anti-Tac antibodies in the year 1998: basiliximab (Simulect) and daclizumab (Zenapax). These drugs act by binding the IL-2a receptor's α chain, preventing...
to target specific cells by conjugating the ICG to antibodies such as daclizumab (Dac), trastuzumab (Tra), or panitumumab (Pan). ICG and laser therapy...
Immunosuppressive drugs such as the therapeutic monoclonal antibody daclizumab, ciclosporin, methotrexate and Adalimumab, sold under the trade name Humira...
receptor. Moreover, for treatment of multiple sclerosis, drug called daclizumab binds to IL2RA and so blocks high-affinity IL-2 receptors on recently...
hematology, and immunology.[citation needed] Investigational MS medicines: Daclizumab High-Yield Process (DAC HYP): is being developed as a potential once-monthly...
therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab. Barnes, LM; Bentley, CM; Dickson, AJ (February 2000)....
colitis by their ability to bind to and inhibit TNF-α. Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help preventing acute rejection...
Global Information
(what is this?) (verify)